$ 1.13
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of LXRX is 2.8 and suggests 145% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
